Search research articles
Contact Us
Filters
Showing results (21-30 of 49) with videos related to
Page
of 5
Sort By:
JCO Precision Oncology
|
December 27, 2021
Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring <i>MET</i> Exon 14 Skipping
Xiuning Le, Lingzhi Hong, Chuck Hensel, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 2, 2017
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer
Martin Reck, Luis Paz-Ares, Paolo Bidoli, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 17, 2020
Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC
Olsi Gjyshi, Ting Xu, Adnan Elhammali, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 9, 2005
Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer
Roy S Herbst, David H Johnson, Eric Mininberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 19, 2025
Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
Melissa L Johnson, Egbert F Smit, Enriqueta Felip, et al.
CA: a Cancer Journal for Clinicians
|
July 9, 2019
Mesothelioma: Scientific clues for prevention, diagnosis, and therapy
Michele Carbone, Prasad S Adusumilli, H Richard Alexander, et al.
JTO Clinical and Research Reports
|
March 31, 2025
Longitudinal Tracking of <i>ALK</i>-Rearranged NSCLC From Plasma Using Circulating Tumor RNA and Circulating Tumor DNA
Simon Heeke, Saumil Gandhi, Hai T Tran, et al.
Future Oncology (London, England)
|
February 15, 2024
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer
Gregory J Riely, Egbert F Smit, Myung-Ju Ahn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 4, 2023
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With
Gregory J Riely, Egbert F Smit, Myung-Ju Ahn, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 2, 2019
Pathologic Considerations and Standardization in Mesothelioma Clinical Trials
Ming-Sound Tsao, Michele Carbone, Francoise Galateau-Salle, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 49) with videos related to
Sort By:
Page
of 5
JCO Precision Oncology
|
December 27, 2021
Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring <i>MET</i> Exon 14 Skipping
Xiuning Le, Lingzhi Hong, Chuck Hensel, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 2, 2017
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer
Martin Reck, Luis Paz-Ares, Paolo Bidoli, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 17, 2020
Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC
Olsi Gjyshi, Ting Xu, Adnan Elhammali, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 9, 2005
Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer
Roy S Herbst, David H Johnson, Eric Mininberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 19, 2025
Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
Melissa L Johnson, Egbert F Smit, Enriqueta Felip, et al.
CA: a Cancer Journal for Clinicians
|
July 9, 2019
Mesothelioma: Scientific clues for prevention, diagnosis, and therapy
Michele Carbone, Prasad S Adusumilli, H Richard Alexander, et al.
JTO Clinical and Research Reports
|
March 31, 2025
Longitudinal Tracking of <i>ALK</i>-Rearranged NSCLC From Plasma Using Circulating Tumor RNA and Circulating Tumor DNA
Simon Heeke, Saumil Gandhi, Hai T Tran, et al.
Future Oncology (London, England)
|
February 15, 2024
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer
Gregory J Riely, Egbert F Smit, Myung-Ju Ahn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 4, 2023
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With
Gregory J Riely, Egbert F Smit, Myung-Ju Ahn, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 2, 2019
Pathologic Considerations and Standardization in Mesothelioma Clinical Trials
Ming-Sound Tsao, Michele Carbone, Francoise Galateau-Salle, et al.
Page
of 5